Biomind Labs Inc.
BMND
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Net Income | 51.50% | 64.65% | 64.36% | 60.06% | 66.44% |
| Total Depreciation and Amortization | -71.79% | -79.75% | -66.75% | -65.61% | -48.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 96.37% | 39.63% | -39.25% | -69.89% | -91.05% |
| Change in Net Operating Assets | -109.82% | -104.21% | -85.28% | 23.33% | 328.03% |
| Cash from Operations | 48.07% | 63.85% | 63.19% | 64.39% | 69.26% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -50.60% | 14.92% | 110.06% | -- | -- |
| Total Debt Repaid | 105.68% | 103.53% | 99.46% | 78.65% | 55.56% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -49.88% | 23.17% | 142.20% | 2,085.68% | -70.72% |
| Foreign Exchange rate Adjustments | 154.39% | -37.26% | 122.90% | 102.58% | 33.07% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 56.97% | 97.16% | 102.04% | 99.92% | 63.41% |